Patient Preferences for Thrombolytic Therapy in Acute Myocardial Infarction

Eric J. Stanek, Judy W.M. Cheng, Patricia J. Peeples, Robert J. Simko and Sarah A. Spinler

Medical Decision Making, 1997, vol. 17, issue 4, 464-471

Abstract: Background. Despite extensive professional debate regarding the optimal thrombolytic therapy strategy in acute myocardial infarction (AMI), patient preferences have not been explored. Methods. Preferences among patients with known or suspected coro nary artery disease for treatment with tissue plasminogen activator (tPA) or streptoki nase (SK) for AMI were determined using a questionnaire presenting GUSTO-1 trial and drug cost data. Preferences were based on consideration of 30-day mortality (M) alone, hemorrhagic stroke rate (SR) alone, overall preference (M + SR), drug acqui sition costs, and the estimated annual costs of using a single agent to treat all AMIs. Cost-related responses were provided under payer designations of self, third-party insurance, and federal government. Results. The response rate was 81% (101/125 patients). tPA was preferred by 84%, and SK by 66%, for M alone and SR alone, respectively (χ 2 , p

Date: 1997
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X9701700412 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:17:y:1997:i:4:p:464-471

DOI: 10.1177/0272989X9701700412

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().